A pioneering Israeli study identifies TRIM63 as a significant genetic contributor to hypertrophic cardiomyopathy (HCM), which could transform genetic screening and treatment protocols. The findings provide compelling evidence for the gene’s role in both causing and increasing susceptibility to HCM.
A large study found moderate protection against SARS-CoV-2 infection and symptomatic Covid-19 illness among vaccinated children, with greater protection observed in younger age subgroups. The research used Israel's Clalit Health Services database to control for confounding variables.
A large real-world study published by Israel's Clalit Research Institute found that parental vaccination with the BNT162b2 vaccine decreased the risk of infection for unvaccinated children by 58.1%, regardless of household size or child age. Vaccination also reduced transmission from infected parents to their unvaccinated children.
A massive Israeli study found that a third COVID-19 vaccine dose reduces hospitalization and severe disease risks by up to 93% compared to two doses. The research provides valuable insights into the effectiveness of booster shots in real-world settings.
The study shows that COVID-19 vaccine effectiveness is substantial in adolescents, with a 93% decrease in symptomatic cases and a 90% decrease in documented infections after the second dose. Vaccine effectiveness was lower but still significant before the second dose.
A large-scale analysis of Israel's COVID-19 vaccination data found that the Pfizer/BioNTech BNT162B2 vaccine is very safe, with only a few potential side effects. The study also revealed that coronavirus infection poses a much higher risk of serious adverse events compared to vaccination.
The study found that the vaccine is highly effective across all age ranges, with 92% effectiveness in preventing symptomatic disease in individuals 70 years and older. Vaccine effectiveness varied among subpopulations, with slightly lower rates in multi-morbid populations and immunosuppressed individuals.
A large-scale peer-reviewed study by the Clalit Research Institute found that the Pfizer vaccine reduces the risk of symptomatic COVID-19 by 94% and severe disease by 92% in fully vaccinated individuals. The study also showed substantial vaccine effectiveness even before completing two doses.